Results 71 to 80 of about 1,481 (180)

Exploring the Comorbidity, Pathophysiology, and Integrated Treatment Strategies of Hypertension and Depression [PDF]

Hypertension and depression are widely prevalent conditions with substantial comorbidity. Hypertension, characterized by persistently elevated arterial pressure, is associated with significant cardiovascular morbidity and mortality.
Adadzi, Jerome, Azi, Cornelius I., Carsrud, N.D. Victor, Flores, John V., Holets, Hilary M., Jomsky, Breanna M., Kerna, Nicholas A., Khan, Maria, Ngwu, Dabeluchi C., Pruitt, Kevin D., Saini, Sawanjit, Taha, Wail Taha Mohammed, Zhao, Xuan   +12 more
core   +2 more sources

A Novel Tertiary Carbamate Prodrug Strategy to Overcome Metabolic Barriers in Oral Ketamine Delivery

ChemMedChem, Volume 21, Issue 2, January 2026.
This study describes the development of an orally optimized ketamine prodrug designed to improve pharmacokinetic properties, extend therapeutic efficacy, and minimize adverse effects and abuse liability. Ketamine, a rapid‐acting N‐methyl‐D‐aspartate (NMDA) receptor antagonist, has therapeutic potential beyond anesthesia, including treatment‐resistant ...
Juulia Järvinen, Santosh Kumar Adla, Janne Tampio, Aaro Jalkanen, Kenneth B. Sloan, Kristiina M. Huttunen, Jarkko Rautio   +6 more
wiley   +1 more source

A Review of Nanoparticle‐Based Astrocyte Modulation in CNS Disorders: Evaluating the Underexplored Potential of Intranasal Delivery

Nano Select, Volume 7, Issue 1, January 2026.
Nanoparticle‐driven nose‐to‐brain drug delivery offers a noninvasive approach to bypass the blood–brain barrier (BBB) and directly modulate reactive astrocytes in CNS disorders. This review highlights biodegradable nanoparticles for astrocyte modulation, enhancing drug bioavailability, sustained release, and neuroinflammation control.
Senamile M. Dlamini, Gillian D. Mahumane, Pradeep Kumar, Yahya E. Choonara   +3 more
wiley   +1 more source

Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality

BMC Psychiatry, 2023
Background Esketamine (ESK) nasal spray, taken with oral antidepressant therapy, is approved for the treatment of depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.
Dong-Jing Fu, Qiaoyi Zhang, Ling Shi, Stephane Borentain, Shien Guo, Maju Mathews, Joana Anjo, Abigail I. Nash, Marguerite O’Hara, Carla M. Canuso   +9 more
doaj   +1 more source

Efficacy and safety of esketamine for "treatment resistant depression": registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials [PDF]

Background: In 2019, the FDA and EMA approved intranasal esketamine for treatment-resistant depression (TRD). The current study re-evaluated its efficacy and safety. Methods: This registered report presents a systematic review and individual patient data
Barbui, Corrado, Cristea, Ioana A, Fodor, Liviu A, Gastaldon, Chiara, Le Pabic, Estelle, Naudet, Florian, Pellen, Claude, Turner, Erick H   +7 more
core   +1 more source

The Ketamine Trial for Acute Suicidality (KETA): Study Protocol of a Double‐Blind Randomized Placebo‐Controlled Superiority Trial on Intranasal Racemic Ketamine Compared to the Active Placebo Intranasal Midazolam as Treatment for Acute Suicidality

International Journal of Methods in Psychiatric Research, Volume 34, Issue 4, December 2025.
ABSTRACT Background Suicidality is a transdiagnostic entity in patients with and without psychiatric disorders. Ketamine is a novel treatment for treatment‐resistant depression with favorable effects on related suicidality in this population. Little is known about the effects of ketamine on suicidality as a distinct phenomenon.
Jurriaan F. M. Strous, Gijs H. J. Roelandt, Jens H. van Dalfsen, Jeanine Kamphuis, Radboud M. Marijnissen, Robert A. Schoevers   +5 more
wiley   +1 more source

Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression [PDF]

Funding Information: This study was sponsored by Janssen EMEA. Support for third\u2011party writing assistance for this article, provided by Phoebe Kennedy, MSc, and Andrew Wilhelmsen, PhD, Costello Medical, UK, was funded by Janssen EMEA in accordance ...
Bitter, Istvan, Buyze, Jozefien, Fagiolini, Andrea, Godinov, Yordan, Gorwood, Philip, Ito, Tetsuro, McIntyre, Roger S., Oliveira-Maia, Albino J., Reif, Andreas, Vieta, Eduard, Werner-Kiechle, Tamara, Young, Allan H.   +11 more
core   +2 more sources

Development and Validation of a Rapid LC–MS/MS Method for Plasma Analysis of Ketamine, Norketamine, Dehydronorketamine, and Hydroxynorketamine

Biomedical Chromatography, Volume 39, Issue 9, September 2025.
ABSTRACT Ketamine, a well‐established dissociative anesthetic, has recently gained significant attention for its rapid‐acting antidepressant effects, particularly in treatment‐resistant depression. In this study, we developed and validated a state‐of‐the‐art liquid chromatography–tandem mass spectrometry (LC–MS/MS) method for the bioanalysis of ...
Jan Thomann, Selina Kraus, Livio Erne, Severin B. Vogt, Matthias E. Liechti, Dino Luethi   +5 more
wiley   +1 more source

The Possible Application of Ketamine in the Treatment of Depression in Alzheimer’s Disease

Neurology International, 2022
Depression is a leading cause of disability globally, with a prevalence of 3.8% among the whole population, 5% of the adult population, and 5.7% of the elderly population over 60 years of age.
Islam Mohammad Shehata, Waniyah Masood, Nouran Nemr, Alexandra Anderson, Kamal Bhusal, Amber N. Edinoff, Elyse M. Cornett, Adam M. Kaye, Alan D. Kaye   +8 more
doaj   +1 more source

Nonresponse to Ketamine in Treatment‐Resistant Bipolar Depression

Neuropsychopharmacology Reports, Volume 45, Issue 3, September 2025.
This study presents post‐hoc analysis of sociodemographic and clinical features of ketamine nonresponders among treatment‐resistant bipolar depression patients. Non‐response to ketamine is associated with a greater psychiatric comorbidity burden and more frequent history of benzodiazepine use. ABSTRACT Objectives Ketamine is a prototypical rapid‐acting
Zofia Kachlik, Wiesław Jerzy Cubała, Michał Walaszek, Michał Pastuszak, Krzysztof Pastuszak, Aleksander Kwaśny   +5 more
wiley   +1 more source